Zacks: Analysts Anticipate TG Therapeutics Inc (TGTX) to Post -$0.45 EPS
Analysts forecast that TG Therapeutics Inc (NASDAQ:TGTX) will report earnings of ($0.45) per share for the current quarter, Zacks reports. Three analysts have made estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). TG Therapeutics reported earnings per share of ($0.46) in the same quarter last year, which indicates a positive year-over-year growth rate of 2.2%. The firm is scheduled to announce its next earnings report on Thursday, March 14th.
On average, analysts expect that TG Therapeutics will report full-year earnings of ($2.03) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.98). For the next financial year, analysts forecast that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.06) to ($0.96). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 99,001.33% and a negative return on equity of 185.20%.
A number of hedge funds have recently modified their holdings of TGTX. RA Capital Management LLC raised its holdings in TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock valued at $56,266,000 after acquiring an additional 1,806,452 shares during the period. Wells Fargo & Company MN raised its holdings in TG Therapeutics by 2,148.1% during the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock valued at $11,686,000 after acquiring an additional 849,233 shares during the period. BlackRock Inc. raised its holdings in TG Therapeutics by 17.4% during the 2nd quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock valued at $53,667,000 after acquiring an additional 605,844 shares during the period. Renaissance Technologies LLC bought a new stake in TG Therapeutics during the 3rd quarter valued at $1,974,000. Finally, Opaleye Management Inc. raised its holdings in TG Therapeutics by 127.9% during the 2nd quarter. Opaleye Management Inc. now owns 625,000 shares of the biopharmaceutical company’s stock valued at $8,218,000 after acquiring an additional 350,800 shares during the period. 57.30% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:TGTX traded up $0.04 during mid-day trading on Thursday, reaching $5.04. The company had a trading volume of 1,552,400 shares, compared to its average volume of 1,348,560. The stock has a market capitalization of $414.49 million, a PE ratio of -2.64 and a beta of 1.72. TG Therapeutics has a one year low of $4.20 and a one year high of $17.35.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.